Moxidectin is under clinical development by Medicines Development for Global Health and currently in Phase III for Helminthiasis (Parasitic Worm Infestation). According to GlobalData, Phase III drugs for Helminthiasis (Parasitic Worm Infestation) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Moxidectin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Moxidectin overview

Moxidectin is a semisynthetic derivative of nemadectin and acts as an anthelmintic agent. It is formulated as tablets for oral route of administration. Moxidectin is indicated for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. Moxidectin is under investigation for the treatment of scabies, onchocerciasis in children, soil-transmitted helminths, strongyloides, lymphatic filariasis and head lice.

Medicines Development for Global Health overview

Medicines Development for Global Health (MDGHL) is an independent biopharmaceutical company that strives to develop and commercialize medicines and vaccines for unmet medical needs. The company’s pipeline clinical programs include Moxidectin, which is being developed for the treatment of river blindness and scabies; and RV-3-BB rotavirus vaccine, for prevention of rotavirus gastroenteritis in infants and neonates. It is also developing products which are in Phase I and II clinical development, for soil-transmitted helminthes, strongyloides and lymphatic filariasis. MDGHL is headquartered in Melbourne, Victoria, Australia.

For a complete picture of Moxidectin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.